IMM-002
Immunology & Inflammation
PreclinicalActive
Key Facts
About RapaFusyn Pharmaceuticals
RapaFusyn Pharmaceuticals is a private, preclinical-stage biotech based in San Diego, founded in 2018. The company has developed a proprietary platform to create RapaGlues, a unique modality of non-degrading molecular glues that harness the FKBP12 chaperone to target intractable proteins. With a pipeline of eight disclosed programs across oncology and immunology & inflammation, the company is advancing its lead program towards IND and recently secured a significant $44 million Series A financing to fuel its platform and pipeline development.
View full company profileTherapeutic Areas
Other Immunology & Inflammation Drugs
| Drug | Company | Phase |
|---|---|---|
| YUSIMRY® (adalimumab-fkjp) | Meitheal Pharmaceuticals | Approved |
| PS-1001 | Paratus Sciences | Pre-clinical |
| TNFR1 Antagonist | AI Proteins | Discovery |
| Immunology Collaboration (J&J) | Flexomics | Discovery/Research |
| IMM-001 | RapaFusyn Pharmaceuticals | Preclinical |
| IMM-003 | RapaFusyn Pharmaceuticals | Preclinical |